Professor Suzanne Turner
- Professor of childhood cancer biology
- Division of Cellular and Molecular Pathology
Connect
About
Suzanne obtained her PhD from the world-renowned Paterson Institute for Cancer Research and the Christie Hospital in Manchester where she examined the potential toxic side-effects of chemoprotective gene therapy. This work was a collaborative effort with what was at that time the AstraZeneca Central Toxicology Labs at Alderley Edge.
Following this training period Suzanne moved to a research post at the Babraham Institute in Cambridge where under the guidance of Dr Denis Alexander she began to investigate mechanisms of Lymphomagenesis, a subject that she has pursued to become a world-expert in paediatric lymphomas, specifically Anaplastic Large Cell Lymphoma (ALCL). Since 2005, Suzanne has been leading an academic research group at the University of Cambridge within the Department of Pathology and based at the Addenbrooke’s Hospital campus in Cambridge. It is here that Suzanne conducts academic research of an international standard and also teaches and examines aspects of the medical, veterinary and natural science tripos. Suzanne is also director of teaching and deputy head of the Department of Pathology.
In 2007, Suzanne was awarded the prestigious Leukaemia and Lymphoma Research (LLR; now Blood Cancer UK) Bennett Fellowship and in 2012 a further 5-year LLR senior lectureship award. Amongst her achievements are the inception and establishment of the European Research Initiative on ALCL, a study group that brings together scientists from across Europe to foster collaboration and advancement in this important area of health research. Suzanne was also the lead of ‘ALKATRAS’, a European Union Marie Curie Innovative Training Network of 14 research groups in 7 EU countries and is currently non-clinical chair of the European Inter-Group for Collaboration into Childhood Non-Hodgkin Lymphoma (EICNHL), co-chair of the Cancer Research UK (CRUK) Cambridge Centre Paediatric Programme and biological lead for the National Cancer Research Institute (NCRI) paediatric lymphoma Clinical Study Group (CSG). Suzanne collaborates with a wide array of scientists and labs around the world, most notably the Uganda Cancer Institute in Kampala with whom she is working towards finding better therapies for children with cancer.
Amongst her other interests Suzanne is the scientific advisor to the Alex Hulme Foundation and Francesca Richardson Trust. She is also a member of both the American and British Associations for Cancer Research (BACR/AACR), the Children’s Cancer and Leukaemia Group (CCLG) in the UK and the International Society for Paediatric Oncology (SIOP). Suzanne also sits on the scientific committee of SIOP, the CCLG research advisory group, the MHRA plastics, reconstructive and aesthetic surgery (PRASEAG) committee and the European Commission’s Scientific committee on Health, Environmental and Emerging Risks (SCHEER) working group on breast implants and cancer. In addition, she was a member of the international grant review panels of the World Cancer Research Fund and the Swedish Research Council’s medicine and health review panel.
- Fellow Hughes Hall
- Executive committee member and co-lead paediatric programme, Cambridge Cancer Centre
- Coordinator FANTOM Marie Curie Doctoral Training Network (https://fantom-project.eu)
- Coordinator ALKATRAS Marie Curie Innovative Training Network (www.alkatras.erialcl.net)
- Biological studies lead, NCRI paediatric lymphoma clinical studies sub-group
- Chair of the European Research Initiative for ALK-related malignancies (ERIA; www.erialcl.net)
- Past co-chair European Inter-group for Childhood Non-Hodgkin Lymphoma (EICNHL)
- Member the MHRA plastics, reconstructive and aesthetic surgery (PRASEAG) committee and the European Commission’s Scientific committee on Health, Environmental and Emerging Risks (SCHEER) working group on breast implants and cancer
- Past member of the grant panel of the Swedish Research Council’s medicine and health review panel
- Past member of the international grant panel of the World Cancer Research Fund
- Member of the scientific committee of the International Society for Paediatric Oncology (SIOP)
- Scientific advisor to the Alex Hulme Foundation, Francesca Richardson Trust and Oncogene cancer research
- Chief scientific advisor to Melior Capital Management 2020-
- Invited member of the Continuous Update Project (CUP) mechanisms Expert Committee, Worldwide Cancer Research Fund Network, 1st February 2022 - 31st January 2025.
- American Association of Plastic Surgeons 2022 Expert Consensus Panel on BIA-ALCL, 2022
- Children’s Cancer and Leukaemia Group (CCLG) Research Advisory Group (RAG)
- Invited member of the University of Padova PhD collegium
Research
In our lab, we investigate the pathogenesis and aetiology of paediatric cancers towards the development of biomarkers to facilitate kinder, less toxic and novel therapeutic approaches.
Mechanisms of Lymphomagenesis
Lymphoma is a heterogeneous disease class consisting of greater than 40 different sub-types and the incidence of this disease has been increasing year on year. In our research we are making progress towards understanding how and why lymphoma develops and hence in the development of new treatments. We investigate a paradigm of lymphomageneis in which a chromosomal translocation leads to the generation of an oncogene and subsequent presumed transformation of T-cells. The oncogene we work with is Nucleophosmin-Anaplastic Lymphoma Kinase (NPM-ALK), a hyperactive tyrosine kinase generated as a result of a translocation between chromosomes 2 and 5. This event is associated with greater than 90% of cases diagnosed as anaplastic large cell lymphoma (ALCL), a mature T-cell malignancy mainly occurring in paediatric patients. Our research aims to unravel the events leading from the t(2;5) to lymphoma. We use a variety of experimental approaches to reach this goal.
Understanding drug resistance in paediatric cancers
We are also developing a resource of patient derived xenografts of paediatric lymphoma, specifically ALCL and Burkitt lymphoma as well as neuroblastoma. Applying these models, our lab is conducting research to experimentally-induce relapse in an effort to understand clonal evolution of tumour cell growth. With this knowledge in hand, our lab then applies high-throughput drug screens and sequencing approaches to develop novel therapeutic regimens. Alongside, this research activity, we also employ CRISPR/Cas9 screens for the identification of putative mechanisms of drug resistance employing cell lines.
Comparative analysis of endemic and sporadic Burkitt lymphoma
Our lab works together with Jackson Orem at the Uganda Cancer Institute in Kampala, Uganda in an effort to understand the aetiology and pathogenesis of Burkitt lymphoma with a particular emphasis on tumour clonal evolution with treatment. This aspect of our research is supported by Cambridge Africa.
Breast implant associated anaplastic large cell lymphoma (BIA-ALCL)
The most recent addition to the family of ALCL is a form of cancer associated with the presence of textured breast implants. Given our 20 years of experience of working towards understanding the pathogenesis of ALCL, we have turned our attention to unraveling the mechanisms that drive this specific form of cancer.
Group Members:
- Jamie Matthews
- Adiba Khan
- Ana Canadas Garcia
- Ali Hitchborn
- Perla Pucci
- Lucy Hare
- Emily James
- Gill Currie
- Chris Steele
- Carla Vazquez Amos
- Rogier ten Hoopen
- Marta Ferraresso
- Leila Jahangiri
- Aiindrila Dhara
- Callum Malcolm
- Jacques Cornwell
- We collaborate with Dr Amos Burke, a paediatric oncologist based in Birmingham
Current and past graduate students
Name
Funding body/Course
Years of study
Position on leaving my lab
Aiindrila Dhara
EU Marie Curie Doctoral Network FANTOM
2023-2026
Ana Canada-Garcias
MPhil biological sciences
2023-2024
PhD student in Turner lab
Ali Hazlewood
MPhil biological sciences
2023-2024
Callum Malcolm
CRUK Cambridge Centre
2023-2027
N/A
Carla Vasquez-Amos
EU Marie Curie Doctoral Network FANTOM
2023-2027
N/A
Charlotte Barrett
MPhil, self-funded
2022-2023
Research technician
Chris Steele
Departmental studentship
2021-2025
N/A
Alisha Burman
NIHR academic clinical fellow
2021
Clinical training
Emily James
MRC DTP
2021-2025
N/A
Lucy Hare
CRUK Cambridge Centre clinical PhD fellowship
2020-2023
Clinical training
Mun Liew
CRUK
2018-2023
Postdoc in Hong Kong
Jamie Matthews
Alex Hulme Foundation PhD
2017-2022
Postdoc in Turner lab
Nina Prokoph
EU Marie-Curie ALKATRAS ITN
2016-2020
Postdoc at DKFZ German Cancer Research Center and Heidelberg University Hospital, Prof Marc-Steffan Raab and Niels Weinhold
Stephen Ducray
EU Marie-Curie ALKATRAS ITN
2016-2020
Strategy and Business Consulting for Bayer's R&D sector
Hugo Larose
Department Centenary Fund PhD Studentship
2015-2019
Pharmaceutical consulting
Sorcha Forde
Alex Hulme Foundation PhD
2014-2018
Pharmaceutical Consulting
Liam Lee
CRUK PhD
2013-2017
Merck – Director of medical affairs, oncology
Camilla Fairbairn
BBSRC PhD
2013-2017
Postdoc., Black Belt Therapeutics (now BitBio)
Gavin Garland
BBSRC PhD
2010-2014
Research Associate, MRC Toxicology Unit, Leicester, Prof Anne Willis (now Cambridge)
Timothy Malcolm
LLR PhD
2009-2013
Postdoc., Kudos, Cambridge (now AstraZeneca)
Bola Hanna
MSc, University of Ulm, Germany
2011
PhD, Heidelberg (now postdoc Harvard)
Naushad Moti*
Pakistani Higher Education Commission PhD
2008-2012
Research Associate, Duke-NUS, Singapore, Prof David Virshup (now flow cytometry manager, Australia)
Suzanne Rigby
MRC PhD
2006-2009
Senior Scientist, Horizon Discovery (now executive lead immuno-oncology unit, GSK)
Fiona McDuff
Wellcome Trust PhD
2006-2009
Research Associate, University of Cambridge, Prof Gerard Evan (now owner of Fiona Patissiere)
Catrin Youssif
MSc, University of Vienna, Austria
2008-2009
PhD, Barcelona
Teaching and supervision
- Director of teaching, department of pathology, 2023-
- Organiser Part 1B Biology of Disease medical and veterinary science tripos/Natural sciences tripos (MVST/NST) course October 2014-2019
- Cambridge University, Department of Pathology Natural Sciences Tripos Part II ‘modelling cancer in vivo’
- Cambridge University, Department of Pathology Part 1B (second year) Biology of Disease course, cancer biology to ~450 students
- Lecture on paediatric cancer research to the MRes CRUK Cambridge cancer programme
- Organiser Part 1B histopathology practical classes October 2013-October 2015
- Leading and demonstrating the part 1B natural science tripos and MVST practicals and problem-solving exercises (histology based; immunology, cancer and other diseases), Cambridge University.